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E-mail: dMost analytical methods in metabolomics are based on one of two strategies. The first strategy is
aimed at specifically analysing a limited number of known metabolites or compound classes.
Alternatively, an unbiased approach can be used for profiling as many features as possible in a
given metabolome without prior knowledge of the identity of these features. Using high-resolution
mass spectrometry with instruments capable of measuring m/z ratios with sufficiently low mass
measurement uncertainties and simultaneous high scan speeds, it is possible to combine these two
strategies, allowing unbiased profiling of biological samples and targeted analysis of specific
compounds at the same time without compromises. Such high mass accuracy and mass resolving
power reduces the number of candidate metabolites occupying the same retention time andm/z ratio
space to a minimum. In this study, we demonstrate how targeted analysis of phospholipids as well as
unbiased profiling is achievable using a benchtop orbitrap instrument after high-speed reversed-
phase chromatography. The ability to apply both strategies in one experiment is an important step
forward in comprehensive analysis of the metabolome. Copyright # 2009 John Wiley & Sons, Ltd.Metabolomics and lipidomics are relatively new scientific
disciplines, currently driven by the performance of the
analytical instrumentation used. Advancements in these
disciplines are often the result of new developments in mass
spectrometry,1,2 or new tools to interrogate the experimental
data.3 Metabolomics and lipidomics research usually follows
one of two possible strategies.4 If metabolic profiling or
fingerprinting is essential, data acquisition techniques focus
on capturing as many metabolites as possible without
initially requiring specific knowledge of the identity of these
analytes.5 Multi-variate statistics is used to determine the
analytes of interest and these are subsequently classified or
identified.6 This strategy is particularly useful in the search
for new compounds, biomarkers, or mechanisms. Some
scientists argue that this method is of limited use when data
will be integrated with other omics platforms such as
proteomics or transcriptomics,7 where unidentified analytes
obstruct the formation and integration of biochemical net-
works. For these researchers, it is useful to only collect data
on known compounds as they can be interpreted in a
biochemical sense.8 As the specific, targeted analysis of
known compounds demands a different method (e.g.,
tandem mass spectrometry, MS/MS) than global metabolic
profiling (usually full scanMS spectra), themerger of the twondence to: D. A. Volmer, Medical Research Council,
dowson Laboratory, Cambridge CB1 9NL, UK.
ietrich.volmer@mrc-hnr.cam.ac.ukstrategies would usually result in compromised quality for
one or the other of the two strategies. The ability to obtain
mass spectra with a very high degree of mass accuracy at
sufficient mass resolutions and scan rates opens the possi-
bility for combining both strategies without any such compro-
mises. Analytical instruments capable of high-resolution mass
measurements are time-of-flight (TOF), Fourier transform ion
cyclotron resonance (FT-ICR) and orbitrap mass spectrometers.
The acquisition of experimental data of sufficient mass
resolving power and accuracy has until a few years ago only
been possible using FT-ICR-MS, with severe limitations with
respect to scan speeds, however. Consequently, FT-ICR instru-
ments have not been routinely applied in high-throughput
metabolomics applications. Higher scan speeds are achiev-
able with a TOF analyser but these do not reach the same
mass accuracy and resolution.9–11 For very complex samples,
both high resolving power and mass accuracy are required,
as available from FT-ICR or orbitrap instruments.12–16 High-
resolution orbitrap mass spectrometry is particular interest-
ing for hyphenated LC/MS applications using ultra-
performance liquid chromatography (UPLC) instruments,
where sub-2mm particle columns generate chromatography
peaks with peak widths of only a few seconds, requiring at
least 2 scans per second to obtain a sufficient number of data
points across the peak for quantitation.
Importantly, if high mass accuracy can be maintained in
metabolomics applications throughout the duration of the
chromatographic experiments, it will be possible to extractCopyright # 2009 John Wiley & Sons, Ltd.
1412 A. Koulman et al.ion chromatograms with a sufficiently high degree of
accuracy, so that overlapping isobaric signals from salt
adducts and lipids containing longer unsaturated fatty acids
can be readily separated. Such applications typically require
5 ppm or less mass measurement accuracy.5
The aim of the present study is to evaluate a second-
generation, benchtop orbitrap mass spectrometry system for
application to high-throughput metabolic profiling. Specifi-
cally, we are describing the analysis of human plasma
samples, with the goal of achieving simultaneous unbiased
fingerprinting as well the targeted analysis of large numbers
ofmetabolites within a single run, without compromising the
analytical quality of the two strategies used.EXPERIMENTAL
Samples
Plasma samples were collected from 10 healthy volunteers.
For each sample, 200mL aliquotswere taken and dilutedwith
either (a) 100mL of Ringer solution; (b) 40mL of Ringer
solution and 10mL of palmitic acid stock solution; (c) 40mL of
Ringer solution and 10mL of glucose stock; (d) 40mL of
Ringer solution and 10mL of N-octanoylsphingosine stock;
(e) 40mL of Ringer solution, 10mL of palmitic acid stock,
10mL of glucose, 10mL ofN-octanoylsphingosine stock. Also,
250mL of whole plasma was used, yielding a set of total 60
samples. A volume of 250mL of each sample was added to
1000mL of cold acetronitrile. This mixture was centrifuged
for 10min at 13 000 rpm and the supernatant was diluted
(1:1) with formic acid (0.1%) and transferred to a 96-well
plate ready for analysis by high-performance liquid chroma-
tography (HPLC).
Chemicals and stock solutions
All chemicals were purchased from Sigma Aldrich (Gilling-
ham, UK) except for N-octanoylsphingosine, which was
supplied by Cayman Chemical Company (Ann Arbor, USA).
Ringer solution was prepared by adding 6.5 g of NaCl, 0.14 g
of KCl, 0.065 g of NaH2PO4, 2 g of glucose, 0.4 g of NaHCO3
and 1mL of 1M CaCl2 to 1 L of H2O. Palmitic acid stock
solution was prepared by dissolving 6.1mg of palmitic acid
in 0.5mL of acetonitrile, N-octanoylsphingosine stock by
dissolving 2mg of N-octanoylsphingosine in 0.5mL of
acetonitrile and glucose stock by dissolving 300mg of
glucose in 0.5mL of H2O.
Chromatography
Chromatographic separations were performed on a
5.0 2.1mm Hypersil Gold 1.9mm C18 column (Thermo
Scientific, Runcorn, UK) using an Accela U-HPLC system
(Thermo Scientific, Hemel Hempstead, UK). The columnwas
maintained at 458C. A binary mobile phase system was used
where A¼ formic acid (0.1%) and B¼ acetonitrile/isopropyl
alcohol (1:1) containing formic acid (0.1%). The mobile phase
program at an initial hold (0.0–0.5min) at 5% B followed by a
linear gradient 5–50% B (0.5–5.0min), then 50–95% B (5.0–
5.5min); the conditions were then held at 95% B (5.5–6.5min)
and returned to the initial conditions (6.5–10.0min). The total
analysis duration was 10min at a flow rate of 0.25mL/min.
The column eluent was directed to the mass spectrometer.Copyright # 2009 John Wiley & Sons, Ltd.The 60 samples were run in randomised order and were
injected using an injection volume of 10mL. This sequence
was repeated with the same injection volume and then two
more times with an injection volume of 5mL giving a total of
240 consecutive injections.
Mass spectrometry
Mass spectrometry was performed on an Exactive orbitrap
mass spectrometer (Thermo Scientific, Hemel Hempstead,
UK) operating in positive ion mode. The heated electrospray
(HESI-II) source was used. The sheath gas was set to 20
(arbitrary units) at a temperature of 2008C, the aux gas set
to 10 (arbitrary units) and the capillary temperature set to
2508C. The capillary voltage and spray voltage were set to
51V and 4.2 kV, respectively. The instrument was operated
in full scan mode from m/z 150–1000 at 50 000 resolving
power. The data acquisition rate was 2Hz. The mass
spectrometer was mass calibrated just prior to starting the
sequence of 240 injections. All data was acquired using lock
mass calibration (m/z 214.0896).
Data analysis
Specific analysis of phosphocholine lipids
For the targeted analysis of 50 specific phospholipids (see
Table 2), the theoretical exact masses were used with 4
significant figures with a scan width of 2.5 ppm. The
resulting extracted ion chromatograms were integrated and
the area-under-the-curve (AUC) was used for relative quan-
titation. The values were imported into the Dante software,17
wheremissing datawas imputed using the kNearest Neighbour
method. Data was further analysed using analysis of
variance (ANOVA), principle component analysis (PCA)
and partial least-squares data analysis (PLS-DA).
MZmine
The raw files were converted into NETcdf files using the
Thermo software package Xcalibur. The converted files
were imported into MZmine18 and peaks were detected
using the following settings: noise level¼ 30000.0; mass
resolution¼ 30000; peak model function¼ ‘Savitzky-Golay’;
min time span¼ 7.0; m/z tolerance¼ 0.0020. The resulting
peak lists were aligned using m/z tolerance¼ 0.0025; reten-
tion time tolerance¼ 10.0%. The resulting peak list was
exported as a CSV file and imported into DANTE17 where
missing data was imputed using the k Nearest Neighbour
method, and data was further analysed using ANOVA, PCA
and PLS-DA.RESULTS AND DISCUSSION
This study evaluates a novel, second-generation orbitrap
mass spectrometer for simultaneous targeted and non-
targeted lipidomics analysis. The previous generation orbi-
trap instrument was an expensive, hybrid design, with linear
ion trap for MSn front-end prior to high-resolution orbitrap
mass analysis. The instrument used in this study is the
second-generation, non-hybrid design, consisting of only the
orbitrap mass analyser, with mass revolving capabilities of
100 000 at scan repetition rates of 1Hz. Scanning is possible atRapid Commun. Mass Spectrom. 2009; 23: 1411–1418
DOI: 10.1002/rcm
Table 1. The stability of the mass accuracies across a 240 sample batch. The spread of the measuredm/z ratios for five selected
ions is shown for every 40th run
Theoretical m/z Average m/z Stdev m/z Min m/z observed Max m/z observed m/z spread [ppm]
C6H12O6Na
þ 203.05261 203.05264 0.00008 203.05255 203.05281 1.3
C16H35O2NH
þ 274.27406 274.27399 0.00003 274.27396 274.27405 1.2
C24H38O4H
þ 391.28429 391.28433 0.00012 391.28415 391.28455 1.0
C24H51O7NP
þ 496.33977 496.33991 0.00027 496.33945 496.340564 2.3
C46H81O8NP
þ 806.59643 806.56943 0.00044 806.56830 806.57050 2.7
Table 2. The post-run targeted analysis of 50 phoshopholipids using their theoretical, exact masses. In three runs (#25, #150,
#240) across the batch of 240 runs, the measuredm/z ratios are reported as well as their deviation from the calculated theoretical
m/z. In addition, the average measured m/z is given for 10 runs (#25, #50, #75, #100, #125, #150, #175, #200, #225 and #240)
Lipid name Calc. (m/z)
Run 25 Run 150 Run 240
Average m/z
(stdev, n¼ 10)
Rt
(min) m/z
Error
(ppm)
Rt
(min) m/z
Error
(ppm) Rt m/z
Error
(ppm)
GPCho(14:0/0:0) 468.3085 6.62 468.3087 0.4 6.61 468.3082 0.6 6.6 468.3084 0.2 468.3084 0.0003
GPEtn(18:1/0:0) 480.3085 6.92 480.3088 0.6 6.9 480.3084 0.2 6.88 480.3091 1.2 480.3086 0.0004
GPCho(O-16:1) 480.3449 7.01 480.3453 0.8 7 480.3447 0.4 6.98 480.3449 0.0 480.3449 0.0005
GPEtn(18:0/0:0) 482.3241 6.75 482.3234 1.5 6.73 482.3235 1.2 6.72 482.3247 1.2 482.3239 0.0004
GPCho(O-16:0) 482.3605 7.08 482.3602 0.6 7.06 482.36 1.0 7.04 482.36 1.0 482.3602 0.0004
GPCho(16:1/0:0) 494.3241 6.67 494.3239 0.4 6.66 494.3241 0.0 6.65 494.3241 0.0 494.3242 0.0002
GPCho(16:0/0:0) 496.3398 6.89 496.3398 0.0 6.87 496.3398 0.0 6.86 496.3398 0.0 496.3398 0.0003
GPEtn(20:4/0:0) 502.2928 6.69 502.2932 0.8 6.68 502.293 0.4 6.67 502.293 0.4 502.2929 0.0004
GPCho(O-18:1) 508.3762 7.10 508.3763 0.2 7.1 508.3755 1.4 7.09 508.3765 0.6 508.3760 0.0005
GPCho(18:3/0:0) 518.3241 6.59 518.3243 0.4 6.57 518.3241 0.0 6.57 518.3239 0.4 518.3240 0.0003
GPCho(18:2/0:0) 520.3398 6.72 520.3392 1.2 6.71 520.3396 0.4 6.7 520.3393 1.0 520.3397 0.0004
GPCho(18:1/0:0) 522.3554 6.93 522.3554 0.0 6.91 522.3555 0.2 6.9 522.3557 0.6 522.3554 0.0004
GPCho(18:0/0:0) 524.3711 7.22 524.3708 0.6 7.19 524.3715 0.8 7.18 524.3701 1.9 524.3709 0.0005
GPEtn(22:6/0:0) 526.2938 6.64 526.2928 1.9 6.62 526.2929 1.7 6.61 526.2928 1.9 526.2930 0.0003
GPCho(20:5/0:0) 542.3241 6.55 542.3240 0.2 6.54 542.3238 0.6 6.53 542.3236 0.9 542.3237 0.0003
GPCho(20:4/0:0) 544.3398 6.69 544.3398 0.0 6.68 544.3399 0.2 6.67 544.3405 1.3 544.3397 0.0005
GPCho(20:3/0:0) 546.3554 6.80 546.3552 0.4 6.79 546.3551 0.5 6.78 546.3545 1.6 546.3552 0.0003
GPCho(22:6/0:0) 568.3398 6.65 568.3398 0.0 6.64 568.3396 0.4 6.63 568.3398 0.0 568.3399 0.0003
SM(d18:1/14:0) 675.5436 6.9 675.5426 1.5 6.9 675.5432 0.6 6.83 675.5428 1.2 675.5433 0.0007
SM(d18:1/15:0) 689.5592 6.69 689.5597 0.7 6.69 689.5599 1.0 nd 689.5594 0.0008
SM(d18:1/16:1) 701.5592 6.97 701.5588 0.6 6.97 701.5587 0.7 6.69 701.5586 0.9 701.5588 0.0004
GPCho(O-34:3) 742.5745 7.38 742.5746 0.1 7.37 742.5755 1.3 7.32 742.5739 0.8 742.5753 0.0008
GPCho(O-34:2) 744.5902 nd 7.43 744.59 0.3 7.34 744.5899 0.4 744.5895 0.0006
GPCho(34:4) 754.5381 6.97 754.5369 1.6 nd 6.81 754.5389 1.1 754.5379 0.0010
GPCho(34:3) 756.5538 7.40 756.5548 1.3 7.39 756.5541 0.4 7.34 756.5533 0.7 756.5538 0.0008
GPCho(34:2) 758.5694 6.89 758.5690 0.5 6.83 758.569 0.5 6.68 758.5701 0.9 758.5695 0.0006
GPCho(34:1) 760.5851 7.23 760.5854 0.4 7.37 760.5854 0.4 7.37 760.5852 0.1 760.5855 0.0004
GPCho(O-36:6) 764.5589 7.09 764.5590 0.1 7.05 764.5579 1.3 nd 764.5588 0.0005
GPCho(O-36:5) 766.5745 7.41 766.5736 1.2 7.39 766.5743 0.3 7.33 766.5738 0.9 766.5740 0.0008
GPCho(O-36:3) 770.6058 7.32 770.6055 0.4 7.3 770.6067 1.2 7.35 770.6067 1.2 770.6061 0.0009
GPCho(36:5) 780.5538 7.38 780.5532 0.8 7.36 780.5537 0.1 7.32 780.5532 0.8 780.5537 0.0010
GPCho(36:4) 782.5694 7.43 782.5703 1.2 7.39 782.5698 0.5 7.34 782.5692 0.3 782.5696 0.0009
GPCho(36:3) 784.5851 7.37 784.5856 0.6 7.39 784.5851 0.0 7.33 784.5851 0.0 784.5845 0.0009
GPCho(36:2) 786.6007 7.04 786.6006 0.1 7.04 786.6002 0.6 6.99 786.6005 0.3 786.6004 0.0006
GOCho(O-38:7) 790.5745 nd 7.4 790.5748 0.4 7.32 790.5737 1.0 790.5743 0.0008
GPCho(O-38:6) 792.5902 7.42 792.5895 0.9 7.39 792.5901 0.1 7.33 792.5902 0.0 792.5897 0.0009
GPCho(O-38:5) 794.6058 7.40 794.6063 0.6 7.38 794.6064 0.8 7.32 794.605 1.0 794.6056 0.0008
GPCho(O-38:4) 796.6215 nd 7.37 796.6219 0.5 7.36 796.6206 1.1 796.6218 0.0009
GPCho(38:7) 804.5538 7.37 804.5524 1.7 7.19 804.5528 1.2 nd 804.5524 0.0003
GPCho(38:6) 806.5694 7.39 806.5692 0.2 7.35 806.5694 0.0 7.35 806.5682 1.5 806.5690 0.0009
GPCho(38:5) 808.5851 7.41 808.5857 0.7 7.39 808.585 0.1 7.33 808.5835 2.0 808.5846 0.0008
GPCho(38:4) 810.6007 7.4 810.6013 0.7 7.42 810.6004 0.4 7.34 810.6003 0.5 810.6007 0.0007
GPCho(38:3) 812.6164 7.4 812.6167 0.4 7.39 812.6174 1.2 nd 812.6174 1.2 812.6164 0.0009
GPCho(O-40:6) 820.6215 nd 7.37 820.6201 1.7 7.32 820.6212 0.4 820.6214 0.0012
GPCho(40:7) 832.5851 7.40 832.5851 0.0 7.37 832.5854 0.4 7.52 832.5836 1.8 832.5844 0.0010
GPCho(40:6) 834.6007 7.14 834.6013 0.7 7.08 834.6006 0.1 nd 834.6006 0.0010
GPCho(40:5) 836.6164 7.4 836.6169 0.6 nd 7.35 836.6147 2.0 836.6170 0.0011
Lipid nomenclature was used according to Lipid Maps.21
nd: not detected; Rt: retention time.
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1414 A. Koulman et al.higher rates, however, with greatly reduced mass resolving
powers. To our knowledge, this is the first report on the
analytical performance on this second-generation orbitrap
mass analyser.
The data presented in this study was obtained from a
single batch of plasma samples consisting of a total of
240 LC/MS runs. The analytical quality of the data was
evaluated using several protocols for five selected com-
pounds; the retention times and mass accuracies were
checked manually for every 40th sample. The robustness of
the mass accuracies was tested by determining the range of
the measured m/z ratios across the top of the peaks for a
width of five scans (for the scan with the highest intensity
and two scans each before and after). Table 1 summarizes the
mean, standard deviation, and lowest and highest measured
m/z ratios for the five test analytes. Overall, the observed
mass measurement uncertainties using the new orbitrap
were comparable to the previous generation orbitrap as well
as standard FT-ICR instuments.19
The stability of the measurements across the 240 runs
demonstrated that the observed mass accuracies were
sufficiently stable to extract ion chromatograms based on
very narrowmass windows. The results in Table 1 suggested
a 2.5 ppm window centred on the theoretical exact masses
of the metabolites to deliver extracted chromatograms thatFigure 1. Extracted ion chromatograms for m/z 496.3398 and 51
middle two traces for 5.0 ppm and bottom traces for 10 pp
chromatogram for m/z 518.3241 is specific for GPCho (18:3/0:
the Naþ adduct of GPCho (16:0/0:0).
Copyright # 2009 John Wiley & Sons, Ltd.can be readily used for quantitation without significant
isobaric interferences. Indeed, increasing the mass uncer-
tainty windows did not increase the area-under-the-curve
(AUC) of the investigated, well-resolved chromatography
peaks, showing that the chosen 2.5 ppm windows captured
all ions across the peak for those ions. For some isobaric ions,
however, increasing the uncertainty allowance yielded the
incorporation of other masses, as exemplified in Fig. 1. The
figure shows that after increasing the ppmwindow to values
>2.5 ppm, it was no longer possible to distinguish two
important Mþ 22 species, generated by either sodiation or
the addition of two carbons and a further unsaturation site.
In our experiments, 2.5 ppmwas considered the largest mass
uncertainty window for quantitative ion extractions from
plasma samples, as confirmed by a suggestion in the
literature.5
Importantly, because the theoretical masses can be used
for ion extraction, it becomes possible to query the data with
a list of theoretical candidate metabolites, without the need
for any prior experimental screening, results or evidence.
Absolute quantitation will of course be obscured by the lack
of standards and commonly observed problems such as ion
suppression and other matrix effects. The real advantage of
this fast scanning procedure, however, is the post-acquisition
availability of accurate mass information for any ion in the8.3241. The top two traces are shown for 2.5 pm windows,
m. Only using the 2.5 ppm windows, the extracted ion
0), while the larger window shows an additional signal for
Rapid Commun. Mass Spectrom. 2009; 23: 1411–1418
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Figure 2. PCA based on (a) 5mL and (b) 10mL injection using post-run targeted analysis of 50 phospholipids with six
samples per volunteers; showing PC1 and PC3 with the eigenvalues in brackets. (The labels refer to different
volunteers from whom the plasma samples originated.) This figure is available in colour online at www.interscience.
wiley.com/journal/rcm
Copyright # 2009 John Wiley & Sons, Ltd. Rapid Commun. Mass Spectrom. 2009; 23: 1411–1418
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Figure 3. (a) PLS-DA analysis of samples fortified with the ceramide N-octanoylsphin-
gosine, based on unsupervised data extraction using MZMine; showing PC1 and PC2
with the eigenvalues in brackets. (þ samples fortified with N-octanoylsphingosine; –
samples not fortified with N-octanoylsphingosine.) (b) PLS-DA analysis of samples
fortified with the ceramide glucose, based on unsupervised data extraction using
MZMine; showing PC1 and PC2 with the eigenvalues in brackets. (þ: samples fortified
with glucose; –: samples not fortified with glucose.) This figure is available in colour online
at www.interscience.wiley.com/journal/rcm
Table 3. Loadings from the first component from PCA (see Fig. 3(a))
Measured (m/z) Rt (s) Loading Mol formulae Theoretical (m/z) Identity
408.3834 395.4 0 C26H50O2N
þ 408.38361 (Cer-H2O) H
þ
448.3760 396.6 0.0002 C26H51O3NNa
þ 448.37667 (Cer) Naþ
426.3940 396.8 0.0006 C26H52O3N
þ 426.39445 (Cer) Hþ
873.7631 396.6 0.0008 C52H102O6N2Na
þ 873.76300 2(Cer) Naþ
409.3868 396.9 0.0010 C25
13CH50O2N
þ 409.38696 (Cer-H2O) H
þ-isotope
874.7664 396.5 0.0012 C1351CH102O6N2Na
þ 874.76636 2(Cer)Naþ-isotope
449.3794 396.2 0.0014 C1325CH51O2NNa
þ 449.37947 (Cer) Naþ-isotope
Cer: N-octanoylsphingosine.
Copyright # 2009 John Wiley & Sons, Ltd. Rapid Commun. Mass Spectrom. 2009; 23: 1411–1418
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High-resolution extracted ion chromatography 1417full scan spectrum, with a degree of specificity equal to most
MS/MS assays.20 Furthermore, although MS/MS is very
frequently able to distinguish between isomers, it often has
difficulty in separating compounds with isobaric masses or
near isobaric masses, which can be separated by high-
resolution, extracted ion chromatograms. For example, based
on the theoretical m/z ratios of 50 phosphocholine lipids in
our samples, wewere able to extract 50 species based on their
ion chromatograms (Table 2). The analytical quality of these
results was assessed by determining the variance between
the repeated analyses. Each sample was analysed four times
(2 injecting 10mL and 2 injecting 5mL) and the coefficient
of variance (CV) was determined calculated correcting for
the injection volume.Measurements resulting in a CV of over
20% were rejected. On this basis the first four runs of the
batch were rejected, as well as some of the larger phos-
pholipids in some samples and the low-abundance sphin-
gomyelins in most of the runs using 5mL injections.
We also investigated whether the different levels of these
compounds can be used to differentiate between the different
human volunteers. Integrated peak valueswere used in these
experiments and exported into DANTE.17 (Analytical runs
using 5mL injections and 10mL injections were analysed
separately.) Missing data values were imputed using the k
Nearest Neighbour method. The resulting data were
analysed by PCA (Fig. 2). Both PCA plots show a similar
distribution (using PC1 and PC3). The main difference
between injection volumes is that the samples from volun-
teers 6 and 7 were clearly separated by PC3 in the 10mL
injection series, but this separation was lost with the 5mL
injections. The reason for this phenomenon is that the
predominantly contributing phospholipids (SM(d18:1/16:1)
and SM(d18:1/15:0)) were only minor constituents, mostly
not quantifiable in the 5mL injection experiments. The
loadings contributing to both PCAs are very similar for four
out of the top five, the same for the 5mL and 10mL injections.
Unbiased metabolomics
The experimental data were also ideally suited to analysis by
standard unsupervised metabolomics approaches. To
demonstrate this, the 240 data files were converted into
the NetCDF format and imported into the open-source
software package MZmine.18 This program was used for
peak-picking and peak alignment. The obtained data were
exported as spreadsheets. By using principle component and
partial least-squares (PLS) analyses (see Fig. 3), we were able
to readily identify the different persons fromwhich the blood
samples originated as well as the different fortifications
employed to some of the samples (fortification refers to the
addition of several compounds from different chemical
classes to aliquots of the plasma samples). The fortification
was conducted to retain the normal biological variation of
these samples but have surrogate markers allowing classi-
fication using unbiased profiling. Table 3 illustrates the top
seven loadings from the PLS analysis (see Fig. 3), showing
clear difference between the ceramide-fortified samples and
plasma samples without ceramide addition. Them/z ratios of
these ions yielded molecular formulae for protonated
molecules after water loss, protonated molecules, as well
as sodiated species, etc. The same approach was used forCopyright # 2009 John Wiley & Sons, Ltd.samples fortified with glucose. The separation using PLS
between the two groups was less clear than for ceramide
fortification, as glucose was already present in the plasma
samples, leading only to elevated levels for the fortified
sample group.
The two approaches described in this study exhibit both
advantages and disadvantages. Using selective m/z ratios is
more powerful for distinguishing quantitative differences of
known compounds, while unsupervised profiling is able to
show qualitative differences, for known and unknown com-
ponents. The use of high-resolution mass spectrometry for
metabolomics offers the possibility for both approaches
without compromises; complementary information is obtained
thus circumventing any errors in peak-picking and align-
ment, which are always present. The use of a target list can
also exclude ions for which poor quantitative measurements
are expected due to sample preparation or chromatography.CONCLUSIONS
Based on the initial set of experiments described in this
study, the new benchtop orbitrap instrument offers great
potential for the development of new powerful approaches
in metabolomics and lipidomics. We have shown that
acquired high-resolution data can be used in different
approaches, targeted and untargeted, at the same time,
without compromises in analytical quality, which so far was
not possible in a single assay. We envision the incorporation
of specific mass defects or software tools using databases for
post-run analysis of the data for specific metabolites in the
future. Furthermore, the use of simultaneous MS/MS data
will greatly enhance analytical specificity, however, at the
price of reduced scan speeds. Future developments of the
orbitrap mass analyser have to address the trade-off between
resolving power and scan speed, as increasing the resolving
power significantly above >50 000 comes at the price of
significantly slower scan speeds, not compatible with fast
chromatography anymore.
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